BioMarin Pharmaceutical Inc. (BMRN) PT Raised at Bernstein Following Inozyme Deal
Tweet Send to a Friend
Bernstein SocGen Group analyst William Pickering raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $95.00 (from $94.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
